tetano
Editor, Senior Moderator
Virology
. 2020 Aug 8;549:77-84.
doi: 10.1016/j.virol.2020.07.018. Online ahead of print.
Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019
Jing Tang[SUP] 1 [/SUP], Shu-Xia Zhang[SUP] 1 [/SUP], Jing Zhang[SUP] 1 [/SUP], Xi-Yan Li[SUP] 1 [/SUP], Jian-Fang Zhou[SUP] 1 [/SUP], Shu-Mei Zou[SUP] 1 [/SUP], Hong Bo[SUP] 1 [/SUP], Li Xin[SUP] 1 [/SUP], Lei Yang[SUP] 1 [/SUP], Jia Liu[SUP] 1 [/SUP], Wei-Juan Huang[SUP] 1 [/SUP], Jie Dong[SUP] 1 [/SUP], Da-Yan Wang[SUP] 2 [/SUP]
Affiliations
Abstract
Human infections with highly pathogenic avian influenza (HPAI) H7N9 virus were detected in late 2016. We examined the drug resistance profile of 30 HPAI H7N9 isolates from Mainland of China (2016-2019). Altogether, 23% (7/30) carried neuraminidase inhibitors (NAIs) - resistance mutations, and 13% (4/30) displayed reduced susceptibility to NAIs in neuraminidase (NA) inhibition test. An HPAI H7N9 reassortment virus we prepared was passaged with NAIs for 10 passages. Passage with zanamivir induced an E119G substitution in NA, whereas passage with oseltamivir induced R292K and E119V substitutions that simulated that seen in oseltamivir -treated HPAI H7N9 cases, indicating that the high frequency of resistant strains in the HPAI H7N9 isolates is related to NAIs use. In presence of NAIs, R238I, A146E, G151E and G234T substitutions were found in HA1 region of HA. No amino acid mutations were found in the internal genes of the recombinant virus.
Keywords: Drug resistance; Highly pathogenic avian influenza H7N9; Influenza virus; Neuraminidase inhibitors.
. 2020 Aug 8;549:77-84.
doi: 10.1016/j.virol.2020.07.018. Online ahead of print.
Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019
Jing Tang[SUP] 1 [/SUP], Shu-Xia Zhang[SUP] 1 [/SUP], Jing Zhang[SUP] 1 [/SUP], Xi-Yan Li[SUP] 1 [/SUP], Jian-Fang Zhou[SUP] 1 [/SUP], Shu-Mei Zou[SUP] 1 [/SUP], Hong Bo[SUP] 1 [/SUP], Li Xin[SUP] 1 [/SUP], Lei Yang[SUP] 1 [/SUP], Jia Liu[SUP] 1 [/SUP], Wei-Juan Huang[SUP] 1 [/SUP], Jie Dong[SUP] 1 [/SUP], Da-Yan Wang[SUP] 2 [/SUP]
Affiliations
- PMID: 32853849
- DOI: 10.1016/j.virol.2020.07.018
Abstract
Human infections with highly pathogenic avian influenza (HPAI) H7N9 virus were detected in late 2016. We examined the drug resistance profile of 30 HPAI H7N9 isolates from Mainland of China (2016-2019). Altogether, 23% (7/30) carried neuraminidase inhibitors (NAIs) - resistance mutations, and 13% (4/30) displayed reduced susceptibility to NAIs in neuraminidase (NA) inhibition test. An HPAI H7N9 reassortment virus we prepared was passaged with NAIs for 10 passages. Passage with zanamivir induced an E119G substitution in NA, whereas passage with oseltamivir induced R292K and E119V substitutions that simulated that seen in oseltamivir -treated HPAI H7N9 cases, indicating that the high frequency of resistant strains in the HPAI H7N9 isolates is related to NAIs use. In presence of NAIs, R238I, A146E, G151E and G234T substitutions were found in HA1 region of HA. No amino acid mutations were found in the internal genes of the recombinant virus.
Keywords: Drug resistance; Highly pathogenic avian influenza H7N9; Influenza virus; Neuraminidase inhibitors.